Company Update (NYSE:LLY): J&J says its diabetes drug should have same survival edge as Lilly’s

[Reuters] – Johnson & Johnson said the proven ability of Eli Lilly and Co’s rival Jardiance diabetes drug to save lives in a large clinical trial is a benefit that will likely be . . . → Read More: Company Update (NYSE:LLY): J&J says its diabetes drug should have same survival edge as Lilly’s Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – EXCLUSIVE-US insurers hold back Lilly’s death-defying diabetes drug Company Update (NYSE:LLY): Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events Market Update (NYSE:LLY): U.S. FDA warns on newer class of type 2 diabetes drugs